India's AstraZeneca Pharma up on import nod for liver cancer drug
** AstraZeneca Pharma ASTR.NS rises 2.7% to 6,872.1 rupees; stock's biggest one-day gain since Feb. 3 ** Biopharmaceutical co receives Indian drug regulator's permission to import Durvalumab solution for sale, distribution ** Drug is used to treat patients with a certain type of liver cancer ** Shares mark second-busiest session in about 2 weeks, with more than 11,000 shares traded ** Stock down 8% so far this year, after a 32% gain from 2024 (Reporting by Aleef Jahan in Bengaluru) ((aleefjahan.cs@thomsonreuters.com))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma India Receives Permission To Import And Sell Trastuzumab Deruxtecan For Additional Indication
Brief: Astrazeneca Pharma Says Bhavana Agrawal Resigns As CFO
Brief: Astrazeneca Pharma India Receives Permission To Import And Sell Benralizumab For Additional Indication
Brief: Astrazeneca Pharma India Receives Permission To Import Benralizumab (Fasenra) For Additional Indication
Brief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan